ROCKVILLE, Md., Nov. 20, 2023 /PRNewswire/ -- CBMG Holdings (the 'Company') today announced that following the spin-off of the Company's stem cell business division, it has changed its name to AbelZeta Pharma, Inc. ('AbelZeta'), which will focus on immune cell business. The spin-off, approved by the Company's board of directors and shareholders, allows AbelZeta to focus greater resources on the development of immune cell therapy for cancer and Inflammation & Immunology (I&I) diseases.

ROCKVILLE，Md。，2023年11月20日/PRNewswire/-CBMG Holdings（“公司”）今天宣布，在公司干细胞业务部门分拆后，它已更改为AbelZeta Pharma，Inc。（'AbelZeta'），专注于免疫细胞业务。由公司董事会和股东批准的分拆允许AbelZeta将更多资源集中在开发用于癌症和炎症及免疫学（I＆I）疾病的免疫细胞疗法上。

.

.

Continue Reading

继续阅读

The name AbelZeta articulates our confidence in T-cell based therapies to address aggressive cancers & immune disorders.

AbelZeta这个名字表达了我们对基于T细胞的疗法的信心，以解决侵袭性癌症和免疫疾病。

Post this

发布这个

'We believe the name AbelZeta best reflects our Company's culture and values and is the next step in our growth as a commercially focused immune cell therapeutics company,' said Tony (Bizuo) Liu, Chairman and CEO of the Company. 'Abel is an ancient name long associated with humility, integrity, and conviction, and the Greek letter ζ, or zeta, is a widely recognized component of the T-cell receptor in the immune cell research community.

该公司董事长兼首席执行官托尼（Bizuo）说：“我们相信AbelZeta这个名字最能反映我们公司的文化和价值观，是我们作为商业化免疫细胞治疗公司发展的下一步。”Abel是一个古老的名字，长期以来与谦卑，诚信和信念有关，希腊字母ζ或zeta是免疫细胞研究界广泛认可的T细胞受体成分。

The name AbelZeta articulates our confidence in the T-cell based therapies to deliver transformative treatments to address aggressive cancers and serious immune disorders.'.

AbelZeta这个名字表达了我们对基于T细胞的疗法的信心，以提供转化疗法来解决侵袭性癌症和严重的免疫疾病。

The Company currently has 13 ongoing clinical studies in its immune cell pipeline in the United States and in China.

该公司目前在美国和中国的免疫细胞管道中进行了13项正在进行的临床研究。

About AbelZeta Pharma, Inc.AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases.

关于AbelZeta Pharma，Inc.AbelZeta是一家全球临床阶段生物制药公司，在中国马里兰州罗克维尔和中国上海拥有卓越中心。AbelZeta专注于开发创新和专有的基于细胞的治疗产品，致力于推出利用人体自身免疫系统对抗血液系统恶性肿瘤和实体瘤以及炎症和免疫疾病的定制治疗。

AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.Forward-Looking StatementsStatements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements.

AbelZeta在其早期临床研究卓越中心的自己GMP设施中推进研究和开发，管道由CAR-T和TIL疗法组成。前瞻性声明本通讯中有关计划，战略，具体活动以及其他不描述历史事实的陈述的陈述是前瞻性陈述。

Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control.

前瞻性信息本质上受风险和不确定性的影响，由于多种因素（包括公司报告中不时详述的任何风险），实际结果可能与目前预期的结果有很大差异。此类陈述基于管理层当前的信念和期望，并受到管理层和公司控制之外的重大风险和不确定性的影响。

Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.Company Contact:Sarah KellyDirector of Co.

鉴于这些不确定性，您不应过分依赖这些前瞻性声明，这些声明仅在本声明发布之日起生效。除法律另有要求外，本公司不承担任何义务，明确免责任何义务，以更新，更改或以其他方式修改可能不时进行的任何前瞻性声明，无论是书面或口头声明，无论是由于新信息，未来事件或其他原因。公司联系人：Sarah KellyDirector of Co。